Moleculin Biotech, Inc. Common Stock
MBRX US60855D2009
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Klemp Walter V CEO |
0.37 USD |
675,675 Bought |
250,000 USD |
20/06/2025 | 23/06/2025 |
Klemp Walter V CEO |
0.37 USD |
675,675 Bought |
250,000 USD |
20/06/2025 | 23/06/2025 |
Foster Jonathan P. CFO |
0.37 USD |
270,270 Bought |
100,000 USD |
20/06/2025 | 23/06/2025 |
Foster Jonathan P. CFO |
0.37 USD |
270,270 Bought |
100,000 USD |
20/06/2025 | 23/06/2025 |
Foster Jonathan P. CFO |
0.69 USD |
28,986 Bought |
20,000 USD |
26/12/2023 | 26/12/2023 |
George Robert E. |
0.69 USD |
14,493 Bought |
10,000 USD |
26/12/2023 | 26/12/2023 |
Klemp Walter V CEO |
0.69 USD |
188,404 Bought |
129,999 USD |
26/12/2023 | 26/12/2023 |